Cargando…
Ternatin and improved synthetic variants kill cancer cells by targeting the elongation factor-1A ternary complex
Cyclic peptide natural products have evolved to exploit diverse protein targets, many of which control essential cellular processes. Inspired by a series of cyclic peptides with partially elucidated structures, we designed synthetic variants of ternatin, a cytotoxic and anti-adipogenic natural produ...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
eLife Sciences Publications, Ltd
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4786417/ https://www.ncbi.nlm.nih.gov/pubmed/26651998 http://dx.doi.org/10.7554/eLife.10222 |
_version_ | 1782420548184178688 |
---|---|
author | Carelli, Jordan D Sethofer, Steven G Smith, Geoffrey A Miller, Howard R Simard, Jillian L Merrick, William C Jain, Rishi K Ross, Nathan T Taunton, Jack |
author_facet | Carelli, Jordan D Sethofer, Steven G Smith, Geoffrey A Miller, Howard R Simard, Jillian L Merrick, William C Jain, Rishi K Ross, Nathan T Taunton, Jack |
author_sort | Carelli, Jordan D |
collection | PubMed |
description | Cyclic peptide natural products have evolved to exploit diverse protein targets, many of which control essential cellular processes. Inspired by a series of cyclic peptides with partially elucidated structures, we designed synthetic variants of ternatin, a cytotoxic and anti-adipogenic natural product whose molecular mode of action was unknown. The new ternatin variants are cytotoxic toward cancer cells, with up to 500-fold greater potency than ternatin itself. Using a ternatin photo-affinity probe, we identify the translation elongation factor-1A ternary complex (eEF1A·GTP·aminoacyl-tRNA) as a specific target and demonstrate competitive binding by the unrelated natural products, didemnin and cytotrienin. Mutations in domain III of eEF1A prevent ternatin binding and confer resistance to its cytotoxic effects, implicating the adjacent hydrophobic surface as a functional hot spot for eEF1A modulation. We conclude that the eukaryotic elongation factor-1A and its ternary complex with GTP and aminoacyl-tRNA are common targets for the evolution of cytotoxic natural products. DOI: http://dx.doi.org/10.7554/eLife.10222.001 |
format | Online Article Text |
id | pubmed-4786417 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | eLife Sciences Publications, Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-47864172016-03-17 Ternatin and improved synthetic variants kill cancer cells by targeting the elongation factor-1A ternary complex Carelli, Jordan D Sethofer, Steven G Smith, Geoffrey A Miller, Howard R Simard, Jillian L Merrick, William C Jain, Rishi K Ross, Nathan T Taunton, Jack eLife Biochemistry Cyclic peptide natural products have evolved to exploit diverse protein targets, many of which control essential cellular processes. Inspired by a series of cyclic peptides with partially elucidated structures, we designed synthetic variants of ternatin, a cytotoxic and anti-adipogenic natural product whose molecular mode of action was unknown. The new ternatin variants are cytotoxic toward cancer cells, with up to 500-fold greater potency than ternatin itself. Using a ternatin photo-affinity probe, we identify the translation elongation factor-1A ternary complex (eEF1A·GTP·aminoacyl-tRNA) as a specific target and demonstrate competitive binding by the unrelated natural products, didemnin and cytotrienin. Mutations in domain III of eEF1A prevent ternatin binding and confer resistance to its cytotoxic effects, implicating the adjacent hydrophobic surface as a functional hot spot for eEF1A modulation. We conclude that the eukaryotic elongation factor-1A and its ternary complex with GTP and aminoacyl-tRNA are common targets for the evolution of cytotoxic natural products. DOI: http://dx.doi.org/10.7554/eLife.10222.001 eLife Sciences Publications, Ltd 2015-12-10 /pmc/articles/PMC4786417/ /pubmed/26651998 http://dx.doi.org/10.7554/eLife.10222 Text en © 2015, Carelli et al http://creativecommons.org/licenses/by/4.0/ This article is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use and redistribution provided that the original author and source are credited. |
spellingShingle | Biochemistry Carelli, Jordan D Sethofer, Steven G Smith, Geoffrey A Miller, Howard R Simard, Jillian L Merrick, William C Jain, Rishi K Ross, Nathan T Taunton, Jack Ternatin and improved synthetic variants kill cancer cells by targeting the elongation factor-1A ternary complex |
title | Ternatin and improved synthetic variants kill cancer cells by targeting the elongation factor-1A ternary complex |
title_full | Ternatin and improved synthetic variants kill cancer cells by targeting the elongation factor-1A ternary complex |
title_fullStr | Ternatin and improved synthetic variants kill cancer cells by targeting the elongation factor-1A ternary complex |
title_full_unstemmed | Ternatin and improved synthetic variants kill cancer cells by targeting the elongation factor-1A ternary complex |
title_short | Ternatin and improved synthetic variants kill cancer cells by targeting the elongation factor-1A ternary complex |
title_sort | ternatin and improved synthetic variants kill cancer cells by targeting the elongation factor-1a ternary complex |
topic | Biochemistry |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4786417/ https://www.ncbi.nlm.nih.gov/pubmed/26651998 http://dx.doi.org/10.7554/eLife.10222 |
work_keys_str_mv | AT carellijordand ternatinandimprovedsyntheticvariantskillcancercellsbytargetingtheelongationfactor1aternarycomplex AT sethofersteveng ternatinandimprovedsyntheticvariantskillcancercellsbytargetingtheelongationfactor1aternarycomplex AT smithgeoffreya ternatinandimprovedsyntheticvariantskillcancercellsbytargetingtheelongationfactor1aternarycomplex AT millerhowardr ternatinandimprovedsyntheticvariantskillcancercellsbytargetingtheelongationfactor1aternarycomplex AT simardjillianl ternatinandimprovedsyntheticvariantskillcancercellsbytargetingtheelongationfactor1aternarycomplex AT merrickwilliamc ternatinandimprovedsyntheticvariantskillcancercellsbytargetingtheelongationfactor1aternarycomplex AT jainrishik ternatinandimprovedsyntheticvariantskillcancercellsbytargetingtheelongationfactor1aternarycomplex AT rossnathant ternatinandimprovedsyntheticvariantskillcancercellsbytargetingtheelongationfactor1aternarycomplex AT tauntonjack ternatinandimprovedsyntheticvariantskillcancercellsbytargetingtheelongationfactor1aternarycomplex |